Firebrick Pharma Limited
Research Firebrick Pharma Limited (FRE.AX) on Bullrun: market cap AUD 9.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFRE.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyAUD
- Market capAUD 9.48M
- Financial periodFY2025
- RevenueAUD 293.42K
- Revenue growth1920.5%
- Net income-AUD 2.63M
- Free cash flow-AUD 1.86M
- Gross margin35.7%
Valuation Snapshot
latest market cap is AUD 9.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 293.42K | -AUD 2.63M | -AUD 1.86M | 35.7% | -0.01 | AUD 983.35K | n/a | AUD 1.56M |
| FY2024 | AUD 14.52K | -AUD 1.18M | -AUD 2.35M | -156.9% | -0.01 | AUD 824.78K | n/a | AUD 2.12M |
| FY2023 | AUD 830 | -AUD 6.80M | -AUD 5.78M | 100.0% | -0.04 | AUD 2.35M | n/a | AUD 2.48M |
| FY2022 | AUD 4.12K | -AUD 3.80M | -AUD 4.23M | 100.0% | -0.03 | AUD 7.14M | n/a | AUD 8.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 9.48M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Firebrick Pharma Limited
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Firebrick Pharma Limited's market cap?
Firebrick Pharma Limited's market capitalization is AUD 9.48M.
What does Firebrick Pharma Limited do?
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.